IceCure's ProSense Reports 97.5% Response Rate at EUSOBI 2026
Image
Caesarea, Israel – October 13, 2026 -- IceCure Medical (Nasdaq: ICCM) reported 12-month objective response rates of 97.5% among 40 breast cancer patients treated with ProSense® cryoablation plus endocrine therapy, and 91.7% among 24 patients treated with cryoablation alone, at the European Society of Breast Imaging (EUSOBI) Annual Scientific Meeting 2026 in Maastricht, the Netherlands.
ProSense features in two scientific sessions at the Maastricht meeting
Dr. Lucía Graña-López of Lugo, Spain, presented the clinical potential of cryoablation in "Beyond Biopsy: Image-Guided Therapy in Practice," part of the session "From Target to Treatment: Breast Interventions."